Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.48 |
| ▸ | DRD5 | P21918 | 4/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024700 | 0.85 | DRD3 (0.63) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5077507 | 0.81 | CACNA1F (0.66) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5077509 | 0.80 | DRD3 (0.58) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5026297 | 0.76 | KCNH2 (0.60) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5027723 | 0.75 | KCNH2 (0.56) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5079886 | 0.74 | DRD3 (0.53) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5023972 | 0.74 | KCNH2 (0.77) | KCNH2 | |
| SCHEMBL8302165 | 0.73 | KCNH2 (0.57) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5074794 | 0.73 | KCNH2 (0.61) | SLC6A3CACNA1FDRD5HRH2ADRA1D | |
| SCHEMBL5676553 | 0.73 | CACNA1F (0.49) | SLC6A3CACNA1FDRD5HRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611116-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | Neuromed Technologies, Inc. (CA) | 2006-01-04 | — | — | EP | claimed |
| US-6943168-B2 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES INC. (CA) | 2005-09-13 | — | — | US | claimed |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-30 | — | — | US | claimed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | claimed |
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | SLC6A3 1160/4885CACNA1F 2/4885DRD5 641/4885 |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | SLC6A3 1160/4885CACNA1F 2/4885DRD5 641/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | SLC6A3 1502/4885CACNA1F 23/4885DRD5 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.